Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Breast 2Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Melanoma 101Carcinoma, Non-Small-Cell Lung 88Carcinoma, Renal Cell 54Neoplasm Metastasis 37Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 32Carcinoma, Hepatocellular 32Lung Neoplasms 31Hodgkin Disease 25Neoplasms 24Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Carcinoma, Transitional Cell 20Breast Neoplasms 19Stomach Neoplasms 17Brain Neoplasms 17Prostatic Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 15Multiple Myeloma 14Head and Neck Neoplasms 14Esophageal Neoplasms 14Glioblastoma 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Neuroendocrine Tumors 10Lymphoma 10Recurrence 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

Oxaliplatin 10Capecitabine 9Cisplatin 8Fluorouracil 5Leucovorin 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3atezolizumab 3Nivolumab 3trebananib 2ponatinib 2pembrolizumab 2avelumab 2apatinib 2alectinib 2XELOX 2Standard of Care 2S 1 (combination) 2Radiotherapy 2Radiosurgery 2Ocoxin 2Irinotecan 2Ipilimumab 2Gemcitabine 2Folfox protocol 2Everolimus 2Erlotinib Hydrochloride 2Acupuncture Therapy 2zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Neoplasms × Nivolumab × Clear all
NCT02923934 2024-07-24

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Olivia Newton-John Cancer Research Institute

Phase 2 Completed
120 enrolled
EndocrineGastrointestinalNET

Gastrointestinal Neoplasms, Neuroendocrine Tumors

NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡